Eloralintide vs #Cagrilintide Which #Amylin Agonist is Better? YouTube Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Bhattachar 2026 Diabetes, Obesity and Metabolism Wiley Online Library The evolving landscape of obesity pharmacotherapy Nature Reviews Drug Discovery, 2026 1 Obesity pharmacotherapy has moved from weight loss drugs to cardiometabolic disease modifying therapy Obesity is now framed as a chronic, relapsing, Eloralintide Phase 2 Paper Out: 20% weight loss after 48 weeks : r Zepbound Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry